JP2020525542A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020525542A5 JP2020525542A5 JP2020520422A JP2020520422A JP2020525542A5 JP 2020525542 A5 JP2020525542 A5 JP 2020525542A5 JP 2020520422 A JP2020520422 A JP 2020520422A JP 2020520422 A JP2020520422 A JP 2020520422A JP 2020525542 A5 JP2020525542 A5 JP 2020525542A5
- Authority
- JP
- Japan
- Prior art keywords
- immune complex
- antibody
- items
- item
- complex according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022195061A JP7512361B2 (ja) | 2017-06-23 | 2022-12-06 | Ｒｏｒ１抗体免疫複合体 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762524386P | 2017-06-23 | 2017-06-23 | |
| US201762524388P | 2017-06-23 | 2017-06-23 | |
| US201762524382P | 2017-06-23 | 2017-06-23 | |
| US62/524,382 | 2017-06-23 | ||
| US62/524,388 | 2017-06-23 | ||
| US62/524,386 | 2017-06-23 | ||
| PCT/US2018/039112 WO2018237335A1 (en) | 2017-06-23 | 2018-06-22 | IMMUNOCONJUGUATED ROR1 ANTIBODIES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022195061A Division JP7512361B2 (ja) | 2017-06-23 | 2022-12-06 | Ｒｏｒ１抗体免疫複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020525542A JP2020525542A (ja) | 2020-08-27 |
| JP2020525542A5 true JP2020525542A5 (enExample) | 2021-07-26 |
| JP7245239B2 JP7245239B2 (ja) | 2023-03-23 |
Family
ID=62904676
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520422A Active JP7245239B2 (ja) | 2017-06-23 | 2018-06-22 | Ｒｏｒ１抗体免疫複合体 |
| JP2022195061A Active JP7512361B2 (ja) | 2017-06-23 | 2022-12-06 | Ｒｏｒ１抗体免疫複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022195061A Active JP7512361B2 (ja) | 2017-06-23 | 2022-12-06 | Ｒｏｒ１抗体免疫複合体 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10335496B2 (enExample) |
| EP (1) | EP3641830A1 (enExample) |
| JP (2) | JP7245239B2 (enExample) |
| KR (2) | KR102913213B1 (enExample) |
| CN (1) | CN111587124B (enExample) |
| AU (2) | AU2018289581C1 (enExample) |
| CA (1) | CA3067829A1 (enExample) |
| IL (2) | IL324994A (enExample) |
| MX (2) | MX2019015057A (enExample) |
| TW (1) | TWI804499B (enExample) |
| WO (1) | WO2018237335A1 (enExample) |
| ZA (1) | ZA201908351B (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3006247A1 (en) | 2015-11-25 | 2017-06-01 | Legochem Biosciences, Inc. | Conjugates comprising peptide groups and methods related thereto |
| EP3380126A4 (en) | 2015-11-25 | 2019-07-24 | LegoChem Biosciences, Inc. | ANTIBODY-ACTIVE CONJUGATES WITH BRANCHED LINKERS AND ASSOCIATED METHODS |
| CA3006242A1 (en) | 2015-11-25 | 2017-06-01 | Legochem Biosciences, Inc. | Conjugates comprising self-immolative groups and methods related thereto |
| MX2018016330A (es) | 2016-06-27 | 2020-02-17 | Univ California | Combinaciones para tratamiento del cáncer. |
| AU2018246806B2 (en) | 2017-03-29 | 2022-05-12 | Ligachem Biosciences Inc. | Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof |
| AU2018289581C1 (en) * | 2017-06-23 | 2025-01-30 | VelosBio Inc. | ROR1 antibody immunoconjugates |
| GB201710836D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| GB201710835D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| CA3099680A1 (en) | 2018-05-09 | 2019-11-14 | Legochem Biosciences, Inc. | Compositions and methods related to anti-cd19 antibody drug conjugates |
| CA3128373A1 (en) * | 2019-02-01 | 2020-08-06 | VelosBio Inc. | Cancer treatment with ror1 antibody immunoconjugates |
| CN113710688A (zh) * | 2019-03-26 | 2021-11-26 | 加利福尼亚大学董事会 | 用于治疗血液癌症和实体瘤癌症的嵌合抗原受体修饰的t细胞(car-t) |
| US20220211861A1 (en) * | 2019-05-22 | 2022-07-07 | The Board of Trustees of the Leland Staford Junior University | Drug conjugates and methods of using same |
| CA3139111A1 (en) * | 2019-05-23 | 2020-11-26 | VelosBio Inc. | Anti-ror1/anti-cd3 bispecific binding molecules |
| GB201908886D0 (en) * | 2019-06-20 | 2019-08-07 | Almac Discovery Ltd | Anthracycline derivatives |
| KR20210028544A (ko) * | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
| EP4097137A4 (en) * | 2020-01-30 | 2024-04-17 | Oncternal Therapeutics, Inc. | Combinations of egfr inhibitors and ror1 inhibitors for the treatment of cancer |
| CA3166286A1 (en) | 2020-02-07 | 2021-08-12 | Jeffry D. Watkins | Anti-ror1 antibodies and compositions |
| WO2022011075A1 (en) * | 2020-07-10 | 2022-01-13 | VelosBio Inc. | Novel ror1 antibody immunoconjugates |
| KR20240038138A (ko) * | 2020-07-13 | 2024-03-22 | 리제너론 파마슈티칼스 인코포레이티드 | 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도 |
| CA3188102A1 (en) * | 2020-08-06 | 2022-02-10 | Qing KANG-FORTNER | Therapies for treating aml and uses of rara agonists, hypomethylating agents, and bcl-2 inhibitors |
| JP2023538134A (ja) * | 2020-08-21 | 2023-09-06 | レザルート・サイエンス・インコーポレイテッド | 腫瘍関連マクロファージを標的とするための組成物及び方法 |
| EP4217009A4 (en) * | 2020-09-28 | 2025-09-24 | Navrogen Inc | COMPOSITION AND USE OF OTHERWISE FORMATTED ANTI-MESOTHELIN ANTIBODIES IN THE TREATMENT OF CANCER |
| US11797990B2 (en) | 2020-11-03 | 2023-10-24 | Capital One Services, Llc | Computer-based systems configured to provide multimodal ATM access via mobile devices and methods of use thereof |
| MX2023009746A (es) * | 2021-02-25 | 2023-09-11 | Allygen Group | Conjugados de direccionamiento que comprenden moleculas efectoras y usos de estos. |
| WO2022178751A1 (en) * | 2021-02-25 | 2022-09-01 | Shanghai Allygen Biologics Co., Ltd. | Targeting conjugates comprising effector molecules and uses thereof |
| CA3172530A1 (en) | 2021-02-25 | 2022-09-01 | Spencer PARK | Ror1 targeting chimeric antigen receptor |
| CA3207635A1 (en) * | 2021-03-09 | 2022-09-15 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Ror1 binding protein and use thereof |
| AU2022249381A1 (en) * | 2021-04-02 | 2023-11-09 | Matrivax, Inc. | METHODS AND COMPOSITIONS FOR TREATING <i>CLOSTRIDIODES DIFFICILE</i> INFECTIONS |
| KR20240016249A (ko) | 2021-06-02 | 2024-02-06 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 항체 약물 접합체, 이의 제조 방법, 및 이의 용도 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| AU2022315277A1 (en) | 2021-07-19 | 2024-01-18 | Immunome, Inc. | Immunoconjugates and methods |
| EP4423145A1 (en) | 2021-10-28 | 2024-09-04 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing ror1-binding protein |
| TW202330619A (zh) | 2021-12-28 | 2023-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｒｏｒ１抗體和抗ｒｏｒ１抗體藥物偶聯物及其醫藥用途 |
| US11446286B1 (en) | 2022-02-28 | 2022-09-20 | King Faisal University | Treatment of fungal infections using dabigatran etexilate |
| CN114605493B (zh) * | 2022-04-06 | 2024-06-04 | 联宁（苏州）生物制药有限公司 | 一种抗体偶联药物中间体set0526的合成方法 |
| WO2023196958A2 (en) * | 2022-04-07 | 2023-10-12 | Oncolinx Pharmaceuticals | Tumor and cancer targeting compounds |
| CN114874287B (zh) * | 2022-05-20 | 2024-04-02 | 联宁（苏州）生物制药有限公司 | 一种抗体偶联药物-连接子lnd1042的合成方法 |
| EP4547284A1 (en) | 2022-06-30 | 2025-05-07 | Sutro Biopharma, Inc. | Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates |
| CN119923409A (zh) | 2022-07-26 | 2025-05-02 | (株)爱恩德生物 | 抗ror1抗体及其用途 |
| WO2024032761A1 (en) * | 2022-08-11 | 2024-02-15 | Hansoh Bio Llc | Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof |
| CN117624167B (zh) * | 2022-08-18 | 2026-02-17 | 四川大学 | 吡咯并苯并二氮杂卓-蒽酰亚胺杂交分子及其制备方法和用途 |
| CN115806630A (zh) * | 2022-08-23 | 2023-03-17 | 上海交通大学 | 用于肿瘤免疫/靶向性治疗的pd-1蛋白-细胞毒素偶联物及其制备方法、应用 |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| EP4626482A1 (en) * | 2022-11-30 | 2025-10-08 | Merck Sharp & Dohme LLC | Cancer treatment with an ror1 antibody immunoconjugate and a btk inhibitor |
| WO2024186263A1 (en) | 2023-03-07 | 2024-09-12 | Axcynsis Therapeutics Pte. Ltd. | Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives |
| CN121175072A (zh) * | 2023-04-11 | 2025-12-19 | 浙江博锐生物制药有限公司 | 抗ror1抗体及其药物偶联物 |
| WO2024235120A1 (zh) * | 2023-05-12 | 2024-11-21 | 四川科伦博泰生物医药股份有限公司 | 稠环化合物及其制备方法和用途 |
| WO2025026338A1 (zh) | 2023-07-31 | 2025-02-06 | 石药集团巨石生物制药有限公司 | 具有高药物负载的抗体-药物缀合物及其用途 |
| AU2024316626A1 (en) | 2023-07-31 | 2026-02-19 | CSPC Megalith Biopharmaceutical Co., Ltd. | Anti-ror1 protein antibody and conjugate thereof |
| AU2024316152A1 (en) * | 2023-08-01 | 2026-02-26 | Ho' Ola Therapeutics Inc. | Glycoengineered forms of ror1 antibodies and methods of use |
| WO2025083071A2 (en) * | 2023-10-16 | 2025-04-24 | Hummingbird Bioscience Pte. Ltd. | Antibody-drug conjugates |
| WO2025083185A1 (en) | 2023-10-20 | 2025-04-24 | Athebio Ag | Reducing off-target accumulation of targeted pharmaceutical compounds |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| GB9816575D0 (en) | 1998-07-31 | 1998-09-30 | Zeneca Ltd | Novel compounds |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CN107213469A (zh) | 2003-11-06 | 2017-09-29 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| EP3505191A1 (en) | 2004-11-12 | 2019-07-03 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
| WO2007051077A2 (en) | 2005-10-28 | 2007-05-03 | The Regents Of The University Of California | Methods and compounds for lymphoma cell detection and isolation |
| CL2007001536A1 (es) * | 2006-05-30 | 2008-01-25 | Genentech Inc | Anticuerpos anti-cd22; polinucleotidos que los codifica; vector y celula huesped que los comprende; metodo de fabricacion; metodo de deteccion del anticuerpo en una muestra biologica; inmunoconjugado que comprende al anticuerpo; composicion que lo comprende y su uso para tratar trastornos proliferativos de celulas b. |
| US20090311249A1 (en) * | 2006-06-02 | 2009-12-17 | Luca Gianni | Capecitabine Combination Therapy |
| US20090258442A1 (en) | 2006-08-31 | 2009-10-15 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| ES2547552T3 (es) | 2008-02-01 | 2015-10-07 | Genentech, Inc. | Metabolito de nemorrubicina y reactivos análogos, conjugados anticuerpo-fármaco y métodos |
| DK2265283T3 (da) | 2008-03-18 | 2014-10-20 | Seattle Genetics Inc | Auristatin-lægemiddel-linker-konjugater |
| EP2311842A3 (en) * | 2008-06-24 | 2011-07-13 | Takeda Pharmaceutical Company Limited | PI3K/M TOR inhibitors |
| JP6067222B2 (ja) | 2008-07-15 | 2017-01-25 | ジェネンテック， インコーポレイテッド | アントラサイクリン誘導体コンジュゲート、その調製方法及び抗腫瘍化合物としてのその用途 |
| JP6099976B2 (ja) * | 2009-04-01 | 2017-03-29 | ジェネンテック， インコーポレイテッド | 抗ＦｃＲＨ５抗体および免疫接合体ならびに使用方法 |
| EP2421899B1 (en) * | 2009-04-23 | 2016-06-08 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-human ror1 antibodies |
| EP2496605A1 (en) | 2009-11-02 | 2012-09-12 | Oxford Biotherapeutics Ltd. | Ror1 as therapeutic and diagnostic target |
| CN102712695B (zh) | 2009-12-18 | 2015-01-21 | 堪瑟拉公司 | 能够诱导细胞死亡的ror1生物抑制剂 |
| ES2623057T3 (es) | 2010-04-15 | 2017-07-10 | Medimmune Limited | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas |
| KR101772354B1 (ko) | 2010-04-15 | 2017-08-28 | 시애틀 지네틱스, 인크. | 표적화된 피롤로벤조디아제핀 접합체 |
| WO2011154542A1 (en) | 2010-06-11 | 2011-12-15 | Artisense Pharma Gmbh | Method for selective oligonucleotide modification |
| WO2011159847A2 (en) * | 2010-06-15 | 2011-12-22 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof |
| WO2012045085A1 (en) | 2010-10-01 | 2012-04-05 | Oxford Biotherapeutics Ltd. | Anti-rori antibodies |
| WO2012075158A1 (en) | 2010-12-01 | 2012-06-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ror1 antibodies |
| GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| EP3252076B1 (en) | 2011-01-14 | 2019-09-04 | The Regents Of The University Of California | Diagnostic use of antibodies against ror-1 protein |
| US9526798B2 (en) | 2011-10-14 | 2016-12-27 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| US20130131139A1 (en) | 2011-11-17 | 2013-05-23 | Oregon Health & Science University | Ror1 as a gene target in acute lymphoblastic leukemia |
| EP2814512A1 (en) | 2012-02-16 | 2014-12-24 | UCL Business Plc. | Lysosome-cleavable linker |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| US20150197807A1 (en) | 2012-08-20 | 2015-07-16 | Presidents And Fellows Of Harvard College | Use of nanowires for delivering biological effectors into immune cells |
| US9758591B2 (en) * | 2012-08-24 | 2017-09-12 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis |
| KR101645905B1 (ko) | 2012-10-12 | 2016-08-04 | 스피로즌 살 | 피롤로벤조디아제핀 및 그의 컨주게이트 |
| CA2891280C (en) | 2012-11-24 | 2018-03-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| AR094280A1 (es) | 2012-12-21 | 2015-07-22 | Bioalliance Cv | Enlazantes hidrofilicos auto-inmolantes y conjugados de los mismos |
| AU2014233385C1 (en) | 2013-03-15 | 2019-09-19 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| EP2968582B1 (en) | 2013-03-15 | 2020-07-01 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
| US9295731B2 (en) | 2013-04-01 | 2016-03-29 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| GB2529356B (en) | 2013-04-28 | 2020-12-23 | Genequantum Healthcare Co Ltd | Novel linkers, coupling intermediates, conjugates, preparation method and application thereof |
| WO2014197854A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
| KR101641206B1 (ko) * | 2013-06-24 | 2016-07-22 | 에이비엘바이오 주식회사 | 안정성이 개선된 항체-약물 결합체 및 이의 용도 |
| AU2014286872B2 (en) * | 2013-07-05 | 2020-01-23 | Formation Biologics Inc. | EGFR antibody conjugates |
| WO2015038426A1 (en) | 2013-09-13 | 2015-03-19 | Asana Biosciences, Llc | Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof |
| KR102572149B1 (ko) | 2013-10-11 | 2023-08-30 | 아사나 바이오사이언시스 엘엘씨 | 단백질-폴리머-약물 접합체 |
| CA3187392A1 (en) | 2013-10-15 | 2015-04-23 | Seagen Inc. | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
| JP6117989B2 (ja) * | 2014-03-24 | 2017-04-19 | 株式会社ジーシー | ２ペースト重合性組成物 |
| CA2952961A1 (en) | 2014-06-25 | 2015-12-30 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer |
| CA2953164C (en) * | 2014-07-22 | 2023-04-11 | Iogen Corporation | Process for producing fuel using two fermentations |
| AU2015329965A1 (en) | 2014-10-09 | 2017-04-27 | Engmab Sàrl | Bispecific antibodies against CD3epsilon and ROR1 |
| US20170306044A1 (en) | 2014-10-09 | 2017-10-26 | Engmab Ag | Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer |
| WO2016094873A2 (en) | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| AU2016206457B2 (en) * | 2015-01-16 | 2021-11-11 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ROR1 |
| EP3297671A4 (en) | 2015-05-18 | 2019-02-06 | Eureka Therapeutics, Inc. | ANTI-ROR1 ANTIBODY |
| HK1254836A1 (zh) * | 2015-10-30 | 2019-07-26 | Nbe-Therapeutics Ag | 抗-ror1抗体 |
| MX2018008926A (es) | 2016-01-20 | 2019-01-10 | Scripps Research Inst | Composiciones de anticuerpo contra ror1 y métodos relacionados. |
| TW201734049A (zh) | 2016-01-22 | 2017-10-01 | 健生生物科技公司 | 抗－ｒｏｒ１抗體、ｒｏｒ１ ｘ ｃｄ３雙特異性抗體及使用其之方法 |
| MX2018016330A (es) | 2016-06-27 | 2020-02-17 | Univ California | Combinaciones para tratamiento del cáncer. |
| US20200338210A1 (en) * | 2016-12-22 | 2020-10-29 | Ardeagen Corporation | Anti-ror1 antibody and conjugates thereof |
| AU2018289581C1 (en) | 2017-06-23 | 2025-01-30 | VelosBio Inc. | ROR1 antibody immunoconjugates |
| CA3128373A1 (en) | 2019-02-01 | 2020-08-06 | VelosBio Inc. | Cancer treatment with ror1 antibody immunoconjugates |
-
2018
- 2018-06-22 AU AU2018289581A patent/AU2018289581C1/en active Active
- 2018-06-22 CN CN201880052547.2A patent/CN111587124B/zh active Active
- 2018-06-22 JP JP2020520422A patent/JP7245239B2/ja active Active
- 2018-06-22 MX MX2019015057A patent/MX2019015057A/es unknown
- 2018-06-22 EP EP18740488.4A patent/EP3641830A1/en active Pending
- 2018-06-22 WO PCT/US2018/039112 patent/WO2018237335A1/en not_active Ceased
- 2018-06-22 IL IL324994A patent/IL324994A/en unknown
- 2018-06-22 CA CA3067829A patent/CA3067829A1/en active Pending
- 2018-06-22 KR KR1020217019380A patent/KR102913213B1/ko active Active
- 2018-06-22 TW TW107121603A patent/TWI804499B/zh active
- 2018-06-22 KR KR1020207001376A patent/KR102736878B1/ko active Active
- 2018-07-05 US US16/027,967 patent/US10335496B2/en not_active Ceased
-
2019
- 2019-04-05 US US16/376,238 patent/US20200030454A1/en not_active Abandoned
- 2019-12-13 ZA ZA2019/08351A patent/ZA201908351B/en unknown
- 2019-12-13 MX MX2021007620A patent/MX2021007620A/es unknown
- 2019-12-19 IL IL271575A patent/IL271575B1/en unknown
-
2021
- 2021-07-01 US US17/365,293 patent/USRE50631E1/en active Active
- 2021-11-11 US US17/524,511 patent/US20220133901A1/en active Pending
-
2022
- 2022-12-06 JP JP2022195061A patent/JP7512361B2/ja active Active
-
2024
- 2024-10-18 AU AU2024227446A patent/AU2024227446A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020525542A5 (enExample) | ||
| JP7512361B2 (ja) | Ｒｏｒ１抗体免疫複合体 | |
| JP2018525354A5 (enExample) | ||
| CN110240654A (zh) | 结合cd73的抗体-药物偶联物 | |
| JP2024075668A (ja) | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| HRP20200551T1 (hr) | Axl-specifični konjugati protutijelo-lijek za liječenje raka | |
| JP2012522513A5 (enExample) | ||
| JPWO2021213434A5 (enExample) | ||
| JP2017522871A5 (enExample) | ||
| JP2025170007A (ja) | 抗１９１ｐ４ｄ１２抗体薬物コンジュゲートを含む薬学的組成物、およびその使用方法 | |
| CN110575548A (zh) | 靶向于cd73的抗体-药物偶联物及其制法和用途 | |
| KR20250137203A (ko) | 항체 약물 접합체 | |
| JP7446341B2 (ja) | 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用 | |
| JPWO2020161214A5 (enExample) | ||
| CN120957755A (zh) | 多环类药物偶联物及其制备方法和用途 | |
| US20260021194A1 (en) | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload | |
| Davidkova et al. | Mechanisms of resistance of antibody-drug conjugates—Obstacles to overcome | |
| WO2026011073A1 (en) | Antibody drug conjugates | |
| CN121079107A (zh) | 一种连接子、抗体药物偶联物及其制备方法 | |
| CN121285392A (zh) | 一种抗pdl1抗体-药物偶联物及应用 | |
| CN120923577A (zh) | 大环类药物偶联物及其制备方法和用途 | |
| IL318911A (en) | Humanized antibodies against NECTIN-4 and their drug conjugates | |
| CN121263211A (zh) | 一种抗表皮生长因子受体(egfr)抗体-药物偶联物及其应用 | |
| BR112019027448B1 (pt) | Imunoconjugado compreendendo um anticorpo conjugado a uma porção de fármaco citotóxica, composição farmacêutica e uso dos mesmos | |
| JPWO2023092099A5 (enExample) |